Clinicogenetic and Pathologic Characteristics of CADASIL

  • Kinley A. Roberts
  • Killian E. T. O’Rourke
  • Owen A. Ross


CADASIL is the most common inherited monogenic disorder causing stroke. It is becoming increasingly recognized across many ancestral groups. This chapter presents the salient features of the disorder to assist those unfamiliar with CADASIL to recognize the disorder.


White Matter Lesion Migraine With Aura NOTCH3 Gene Spinal Cord Involvement Autosomal Dominant Condition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We would like to thank all those who have contributed to our research, particularly the patients and families who donated DNA samples for this work. We would like to thank Dr. Eoin Kavanagh (Consultant Radiologist, Mater Misericordiae Hospital, Dublin) for providing the MRI images. OAR is a recipient of a James and Ester King Foundation New Investigator Award, Florida State. OAR is also funded by the American Heart Association (AHA) and the Myron and Jane Hanley Award in Stroke research. For further details on our research in cerebrovascular disease, please visit our Website:


  1. 1.
    Kalimo H, Viitanen M, Amberla K, Juvonen V, Marttila R, Poyhonen M, et al. CADASIL: hereditary disease of arteries causing brain infarcts and dementia. Neuropathol Appl Neurobiol. 1999;25:257–65.PubMedCrossRefGoogle Scholar
  2. 2.
    Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383:707–10.PubMedCrossRefGoogle Scholar
  3. 3.
    Joutel A, Dodick DD, Parisi JE, Cecillon M, Tournier-Lasserve E, Bousser MG. De novo mutation in the Notch3 gene causing CADASIL. Ann Neurol. 2000;47:388–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Vikelis M, Papatriantafyllou J, Karageorgiou CE. A novel CADASIL-causing mutation in a stroke patient. Swiss Med Wkly. 2007;137:323–5.PubMedGoogle Scholar
  5. 5.
    Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Mohr JP. The natural history of CADASIL. Stroke. 1999;30:1230–3.PubMedCrossRefGoogle Scholar
  6. 6.
    Sundal C, Ekholm S, Andersen O. White matter disorders with autosomal dominant heredity: a review with personal clinical case studies and their MRI findings. Acta Neurol Scand. 2010;121:328–37.PubMedCrossRefGoogle Scholar
  7. 7.
    Tikka S, Mykkanen K, Ruchoux MM, Bergholm R, Junna M, Pöyhönen M, et al. Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. Brain. 2009;132(Pt 4):933–9.PubMedGoogle Scholar
  8. 8.
    Werring D, Howard R, Leff A, Shorvon S. Systemic conditions and neurology. In: Clarke C, Howard R, Rossor M, Shorvon S, editors. Neurology, a queen square textbook. 1st ed. New York: Wiley-Blackwell; 2009. p. 932–3.Google Scholar
  9. 9.
    Opherk C, Peters N, Herzog J, Luedtke R, Dichgans M. Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients. Brain. 2004;127:2533–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Sourander P, Walinder J. Hereditary multi-infarct dementia. Morphological and clinical studies of a new disease. Acta Neuropathol. 1977;39:247–54.PubMedCrossRefGoogle Scholar
  11. 11.
    Tornier-Lasserve E, Joutel A, Melki J, Weissenbach J, Lathrop GM, Chabriat H, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genet. 1993;3(3):256–9.CrossRefGoogle Scholar
  12. 12.
    Bousser MG, Tournier-Lasserve E. Summary of the proceedings of the First International Workshop on CADASIL. Paris, May 19–21, 1993. Stroke. 1994;25:704–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Kempster PA, Alty JE. John Ruskin’s relapsing encephalopathy. Brain. 2008;131:2520–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Hemelsoet D, Hemelsoet K, Devreese D. The neurological illness of Friedrich Nietzsche. Acta Neurol Belg. 2008;108(10):9–16.PubMedGoogle Scholar
  15. 15.
    Razvi M, Saif S, Muir KW. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Pract Neurol. 2004;4:50–5.CrossRefGoogle Scholar
  16. 16.
    Razvi SS, Davidson R, Bone I, Muir KW. The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J Neurol Neurosurg Psychiatry. 2005;76(5):739–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Dong Y, Hassan A, Zhang Z, Huber D, Dalageorgou C, Markus HS. Yield of screening for CADASIL mutations in lacunar stroke and leukoariosis. Stroke. 2003;34(1):203–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Ruchoux MM, Maurage CA. CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy. J Neuropathol Exp Neurol. 1997;56(9):947–64.PubMedCrossRefGoogle Scholar
  19. 19.
    Arboleda-Velasquez JF, Lopera F, Lopez E, Frosch MP, Sepulveda-Falla D, Gutierrez JE, et al. C455R Notch3 mutation in a Colombian CADASIL kindred with early onset of stroke. Neurology. 2002;59(2):277–99.PubMedCrossRefGoogle Scholar
  20. 20.
    Dichgans M, Mayer M, Uttner I, Bruning R, Muller-Hocker J, Rungger G, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44(5):731–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Herve D, Chabriat H. CADASIL. J Geriatr Psychiatry Neurol. 2010;23(4):269–76.PubMedCrossRefGoogle Scholar
  22. 22.
    Chabriat H, Joutel A, Vahedi K, iba-Zizen MT, Tournier-Lasserve E, Bousser MG. CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy). J Mal Vasc. 1996;21(5):277–82.PubMedGoogle Scholar
  23. 23.
    Chabriat H, Joutel A, Vahedi K, iba-Zizen MT, Tournier-Lasserve E, Bousser MG. CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy). Rev Neurol. 1997;153(6–7):376–85.PubMedGoogle Scholar
  24. 24.
    Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Chabriat H, Joutel A, Vahedi K, Tournier-Lasserve E, Bousser MG. CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. In: Moht JD, Choi DW, Grotti JC, Weir B, Wolf PA, editors. Stroke: pathophysiology, diagnosis and management, vol. 4. New York: Churchill-Livingstone; 2004. p. 687–92.Google Scholar
  26. 26.
    Choi JC. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: a genetic cause of cerebral small vessel disease. J Clin Neurol. 2010;6:1–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Arboleda-Velasquez JF, Rampal R, Fung E, Darland DC, Liu M, Martinez MC, et al. CADASIL mutations impair Notch3 glycosylation by Fringe. Hum Mol Genet. 2005;14(12):1631–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Meschia JF, Worrall BB, Rich SS. Genetic susceptibility to ischemic stroke. Nat Rev Neurol. 2011;7:369–78.PubMedCrossRefGoogle Scholar
  29. 29.
    Kim Y, Choi EJ, Choi CG, Kim G, Choi JH, Yoo HW, et al. Characteristics of CADASIL in Korea: a novel cysteine-sparing Notch3 mutation. Neurology. 2006;66:1511–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Mazzei R, Conforti FL, Lanza PL, Sprovieri T, Lupo MR, Gallo O, et al. A novel Notch3 gene mutation not involving a cysteine residue in an Italian family with CADASIL. Neurology. 2004;63:561–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Okeda R, Arima K, Kawai M. Arterial changes in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in relation to pathogenesis of diffuse myelin loss of cerebral white matter: examination of cerebral medullary arteries by reconstruction of serial sections of an autopsy case. Stroke. 2002;33:2565–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Scheid R, Heinritz W, Leyhe T, Thal DR, Schober R, Strenge S, et al. Cysteine-sparing notch3 mutations: cadasil or cadasil variants? Neurology. 2008;71:774–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Joutel A, Andreux F, Gaulis S, et al. The ectodomain of the notch receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest. 2000;105:597–605.PubMedCrossRefGoogle Scholar
  34. 34.
    Coto E, Menendez M, Navarro R, Garcia-Castro M, Alvarez V. A new de novo Notch3 mutation causing CADASIL. Eur J Neurol. 2006;13:628–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Baudrimont M, Dubas F, Joutel A, Tournier-Lasserve E, Bousser MG. Autosomal dominant leukoencephalopathy and subcortical ischemic stroke. A clinicopathological study. Stroke. 1993;24(1):122–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Viswanathan A, Gray F, Bousser MG, Baudrimont M, Chabriat H. Cortical neuronal apoptosis in CADASIL. Stroke. 2006;37(11):2690–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Miao Q, Paloneva T, Tuominen S, Poyhonen M, Tuisku S, Viitanen M, et al. Fibrosis and stenosis of the long penetrating cerebral arteries: the cause of the white matter pathology in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Brain Pathol. 2004;14:358–64.PubMedCrossRefGoogle Scholar
  38. 38.
    Kalimo H, Ruchoux MM, Viitanen M, Kalaria RN. CADASIL: a common form of hereditary arteriopathy causing brain infarcts and dementia. Brain Pathol. 2002;12(3):371–84.PubMedCrossRefGoogle Scholar
  39. 39.
    Furby A, Vahedi K, Force M. Differential diagnosis of a vascular leukoencephalopathy within a CADASIL family: Use of skin biopsy electron microscopy study and direct genotype screening. J Neurol. 1998;245:734–40.PubMedCrossRefGoogle Scholar
  40. 40.
    Ruchoux MM, Chabriat H, Bousser MG, Baudrimont M, Tournier-Lasserve E. Presence of ultrastructural arterial lesions in muscle and skin vessels of patients with CADASIL. Stroke. 1994;25(11):2291–2.PubMedCrossRefGoogle Scholar
  41. 41.
    Ebke M, Dichgans M, Bergmann M, Voelter HU, Rieger P, Gasser T, et al. CADASIL: skin biopsy allows diagnosis in early stages. Acta Neurol Scand. 1997;95(6):351–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Joutel A, Favrole P, Labauge P, Chabriat H, Lescoat C, Andreux F, et al. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet. 2001;358(9298):2049–51.PubMedCrossRefGoogle Scholar
  43. 43.
    Chabriat H, Vahedi K, Iba-Zizen MT, Joutel A, Nibbio A, Nagy TG, et al. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet. 1995;346:934–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Reyes S, Viswanathan A, Godin O, Dufouil C, Benisty S, Hernandez K, et al. Apathy: a major symptom in CADASIL. Neurology. 2009;72:905–10.PubMedCrossRefGoogle Scholar
  45. 45.
    Peters N, Herzog J, Opherk C, Dichgans M. A two-year clinical follow-up study in 80 CADASIL subjects: progression patterns and implications for clinical trials. Stroke. 2004;35(7):1603–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalgia. 1988;7(suppl):8.Google Scholar
  47. 47.
    Hutchinson M, O’Riordan J, Javed M, Quin E, Macerlaine D, Wilcox T, et al. Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL). Ann Neurol. 1995;38(5):817–24.PubMedCrossRefGoogle Scholar
  48. 48.
    Verin M, Rollard Y, Landgraf F, Chabriat H, Bompais B, Michel A, et al. New phenotype of the cerebral autosomal dominant arteriopathy mapped to chromosome 19: migraine as a prominent feature. J Neurol Neurosurg Psychiatry. 1995;59:579–85.PubMedCrossRefGoogle Scholar
  49. 49.
    Chabriat H, Tournier-Lasserve E, Vahedi K, Leys D, Joutel A, Nibbio A, et al. Autosomal dominant migraine with MRI white-matter abnormalities mapping to the CADASIL locus. Neurology. 1995;45(6):1086–91.PubMedCrossRefGoogle Scholar
  50. 50.
    Schon F, Martin RJ, Prevett M, Clough C, Enevoldson TP, Markus HS. “CADASIL coma”: an underdiagnosed acute encephalopathy. J Neurol Neurosurg Psychiatry. 2003;74(2):249–52.PubMedCrossRefGoogle Scholar
  51. 51.
    Le Ber I, Carluer L, Derache N, Lalevee C, Ledoze F, Defer GL. Unusual presentation of CADASIL with reversible coma and confusion. Neurology. 2002;59(7):1115–6.PubMedCrossRefGoogle Scholar
  52. 52.
    O’Rourke K, Crumlish N, Murphy D, Stack J, Murray B. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL): a familial cause of depression and headache. Ir J Psych Med. 2010;27:215–6.Google Scholar
  53. 53.
    Kumar SK, Mahr G. CADASIL presenting as bipolar disorder. Psychosomatics. 1997;38(4):397–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Ahearn E, Speer M, Chen Y, Steffens DC, Cassidy F, Van Meter S, et al. Investigation of notch 3 as a candidate gene for bipolar disorder using brain hyperintensities as an endophenotype. Am J Med Genet. 2002;114:652–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Buffon F, Porcher R, Hernandez K, Kurtz A, Pointeau S, Vahedi K, et al. Cognitive profile in CADASIL. J Neurol Neurosurg Psychiatry. 2006;77(2):175–80.PubMedCrossRefGoogle Scholar
  56. 56.
    Taillia H, Chabriat H, Kurtz A, Verin M, Levy C, Vahedi K, et al. Cognitive alterations in non-demented CADASIL patients. Cerebrovasc Dis. 1998;8(2):97–101.PubMedCrossRefGoogle Scholar
  57. 57.
    Peters N, Opherck C, Danek A, Ballard C, Herzog J, Dichgans M. The pattern of cognitive performance in CADASIL; a monogenic condition leading to subcortical ischemic vascular dementia. Am J Psychiatry. 2005;162(11):2078–85.PubMedCrossRefGoogle Scholar
  58. 58.
    Viswanathan A, Godin O, Jouvent E, O’Sullivan M, Gschwendtner A, Peters N, et al. Impact of MRI markers in subcortical vascular dementia: a multi-modal analysis in CADASIL. Neurobiol Aging. 2010;31:1629–36.PubMedCrossRefGoogle Scholar
  59. 59.
    O’Sullivan M, Ngo E, Viswanathan A, Jouvent E, Gschwendtner A, Saemann PG, et al. Hippocampal volume is an independent predictor of cognitive performance in CADASIL. Neurobiol Aging. 2009;30:890–7.PubMedCrossRefGoogle Scholar
  60. 60.
    O’Sullivan M, Barrick TR, Morris RG, Clark CA, Markus HS. Damage within a network of white matter regions underlies executive dysfunction in CADASIL. Neurology. 2005;65:1584–90.PubMedCrossRefGoogle Scholar
  61. 61.
    Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Shungu DC, et al. CADASIL in a North American family: clinical, pathological, and radiologic findings. Neurology. 1998;51(3):844–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Van Gerpen JA, Ahiskog JE, Petty GW. Progressive supranuclear palsy phenotype secondary to CADASIL. Parkinsonism Relat Disord. 2003;9:367–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Wegner F, Strecker K, Schwarz J, Wagner A, Heinritz W, Sommerer F, et al. Vascular parkinsonism in a CADASIL case with an intact nigrostriatal dopaminergic system. J Neurol. 2007;254:1743–5.PubMedCrossRefGoogle Scholar
  64. 64.
    Fattapposta F, Restuccia R, Pirro C, Malandrini A, Locuratolo N, Amabile G, et al. Early diagnosis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL): the role of MRI. Funct Neurol. 2004;19:239–42.PubMedGoogle Scholar
  65. 65.
    Chabriat H, Levy C, Taillia H, Iba-Zizen MT, Vahedi K, Joutel A, et al. Patterns of MRI lesions in CADASIL. Neurology. 1998;51:452–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Dichgans M, Filippi M, Bruning R, Iannucci G, Berchtenbreiter C, Minicucci L, et al. Quantitative MRI in CADASIL: correlation with disability and cognitive performance. Neurology. 1999;52(7):1361–7.PubMedCrossRefGoogle Scholar
  67. 67.
    O’Sullivan M, Jarosz JM, Martin RJ, Deasy N, Powell JF, Markus HS. MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. Neurology. 2001;56(5):628–34.PubMedCrossRefGoogle Scholar
  68. 68.
    Auer DP, Putz B, Gossl C, Elbel G, Gasser T, Dichgans M. Differential lesion patterns in CADASIL and sporadic subcortical arteriosclerotic encephalopathy: MR imaging study with statistical parametric group comparison. Radiology. 2001;218(2):443–51.PubMedGoogle Scholar
  69. 69.
    Markus HS, Martin RJ, Simpson MA, Dong YB, Ali N, Crosby AH, et al. Diagnostic strategies in CADASIL. Neurology. 2002;59(8):1134–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Chabriat H, Mrissa R, Levy C, Vahedi K, Taillia H, Iba-Zizen MT, et al. Brain stem MRI signal abnormalities in CADASIL. Stroke. 1999;30(2):457–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Cumurciuc R, Guichard JP, Reizine D, Gray F, Bousser MG, Chabriat H. Dilation of Virchow-Robin spaces in CADASIL. Eur J Neurol. 2006;13(2):187–90.PubMedCrossRefGoogle Scholar
  72. 72.
    Dichgans M, Holtmannspotter M, Herzog J, Peters N, Bergmann M, Yousry TA. Cerebral microbleeds in CADASIL: a gradient-echo magnetic resonance imaging and autopsy study. Stroke. 2002;33(1):67–71.PubMedCrossRefGoogle Scholar
  73. 73.
    van den Boom R, Lesnik Oberstein SA, Ferrari MD, Haan J, van Buchem MA. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: MR imaging findings at different ages–3rd-6th decades. Radiology. 2003;229(3):683–90.PubMedCrossRefGoogle Scholar
  74. 74.
    Viswanathan A, Chabriat H. Cerebral microhemorrhage. Stroke. 2006;37(2):550–5.PubMedCrossRefGoogle Scholar
  75. 75.
    Peters N, Opherk C, Bergmann T, Castro M, Herzog J, Dichgans M. Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies. Arch Neurol. 2005;62(7):1091–4.PubMedCrossRefGoogle Scholar
  76. 76.
    Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssière C, et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet. 1997;350(9090):1511–5.PubMedCrossRefGoogle Scholar
  77. 77.
    Monet M, Domenga V, Lemaire B, Souilhol C, Langa F, Babinet C, et al. The archetypal R90C CADASIL-NOTCH3 mutation retains NOTCH3 function in vivo. Hum Mol Genet. 2007;16(8):982–92.PubMedCrossRefGoogle Scholar
  78. 78.
    Dichgans M, Wick M, Gasser T. Cerebrospinal fluid findings in CADASIL. Neurology. 1999;53:233.PubMedCrossRefGoogle Scholar
  79. 79.
    Bentley P, Wang T, Malik O, Nicholas R, Ban M, Sawcer S, et al. CADASIL with cord involvement associated with a novel and atypical NOTCH3 mutation. J Neurol Neurosurg Psychiatry. 2011;82(8):855–60.PubMedCrossRefGoogle Scholar
  80. 80.
    Babikian V, Ropper A. Biswanger’s disease: a review. Stroke. 1987;18:2–12.PubMedCrossRefGoogle Scholar
  81. 81.
    O’Riordan S, Nor AM, Hutchinson M. CADASIL imitating multiple sclerosis: the importance of MRI markers. Mult Scler. 2002;8:430e2.Google Scholar
  82. 82.
    Matthews PM, Tampieri D, Berkovic SF, Andermann F, Silver K, Chityat D, et al. Magnetic resonance imaging shows specific abnormalities in the MELAS syndrome. Neurology. 1991;41:1043–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. CADASIL. Lancet Neurol. 2009;8(7):643–53.PubMedCrossRefGoogle Scholar
  84. 84.
    Forteza AM, Brozman B, Rabinstein AA, Romano JG, Bradley WG. Acetazolamide for the treatment of migraine with aura in CADASIL. Neurology. 2001;57(11):2144–5.PubMedCrossRefGoogle Scholar
  85. 85.
    Weller M, Dichgans J, Klockgether T. Acetazolamide-responsive migraine in CADASIL. Neurology. 1998;50(5):1505.PubMedCrossRefGoogle Scholar
  86. 86.
    Choi JC, Kang SY, Kang JH, Park JK. Intracerebral haemorrhages in CADASIL. Neurology. 2005;67:2042–4.CrossRefGoogle Scholar
  87. 87.
    Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1998;95(15):8880–5.PubMedCrossRefGoogle Scholar
  88. 88.
    Peters N, Freilinger T, Opherk C, Pfefferkorn T, Dichgans M. Effects of short term atorvastatin treatment on cerebral hemodynamics in CADASIL. J Neurol Sci. 2007;260(1–2):100–5.PubMedCrossRefGoogle Scholar
  89. 89.
    Singhal S, Bevan S, Barrick T, Rich P, Markus HS. The influence of genetic and cardiovascular risk factors on the CADASIL phenotype. Brain. 2004;127:2031–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Poneh AS, Brice G, Martin RJ, Markus H. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype. Stroke. 2010;41:630–4.CrossRefGoogle Scholar
  91. 91.
    Viswanathan A, Guichard JP, Gschwendtner A, Buffon F, Cumurcuic R, Boutron C, et al. Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study. Brain. 2006;129:2375–83.PubMedCrossRefGoogle Scholar
  92. 92.
    Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008;7:310–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Kinley A. Roberts
    • 1
  • Killian E. T. O’Rourke
    • 2
  • Owen A. Ross
    • 3
  1. 1.Department of NeurologyDublin Neurological InstituteDublin 7Ireland
  2. 2.Department of NeurologyDublin Neurological Institute, Mater Misericordiae University HospitalDublin 7Ireland
  3. 3.Department of NeuroscienceMayo ClinicJacksonvilleUSA

Personalised recommendations